The 36-month beta value for CLRB is at 1.02. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CLRB is 40.04M, and currently, shorts hold a 6.98% of that float. The average trading volume for CLRB on December 31, 2024 was 1.77M shares.
CLRB) stock’s latest price update
Cellectar Biosciences Inc (NASDAQ: CLRB) has seen a rise in its stock price by 2.02 in relation to its previous close of 0.29. However, the company has experienced a 8.05% gain in its stock price over the last five trading sessions. finbold.com reported 2024-12-26 that As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ: SMCI) – though with a sell order placed for April – and myriad Chinese stocks, again, with a sell order for October 1.
CLRB’s Market Performance
Cellectar Biosciences Inc (CLRB) has experienced a 8.05% rise in stock performance for the past week, with a -80.66% drop in the past month, and a -85.68% drop in the past quarter. The volatility ratio for the week is 15.71%, and the volatility levels for the past 30 days are at 13.53% for CLRB. The simple moving average for the past 20 days is -50.83% for CLRB’s stock, with a -87.46% simple moving average for the past 200 days.
Analysts’ Opinion of CLRB
Many brokerage firms have already submitted their reports for CLRB stocks, with Ladenburg Thalmann repeating the rating for CLRB by listing it as a “Buy.” The predicted price for CLRB in the upcoming period, according to Ladenburg Thalmann is $13 based on the research report published on December 05, 2024 of the current year 2024.
ROTH Capital gave a rating of “Buy” to CLRB, setting the target price at $10 in the report published on January 21st of the previous year.
CLRB Trading at -78.46% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.31% of loss for the given period.
Volatility was left at 13.53%, however, over the last 30 days, the volatility rate increased by 15.71%, as shares sank -80.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -85.97% lower at present.
During the last 5 trading sessions, CLRB rose by +6.35%, which changed the moving average for the period of 200-days by -91.57% in comparison to the 20-day moving average, which settled at $0.6056. In addition, Cellectar Biosciences Inc saw -89.25% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLRB
Current profitability levels for the company are sitting at:
- -156.13 for the present operating margin
- 0.32 for the gross margin
The net margin for Cellectar Biosciences Inc stands at -135.05. The total capital return value is set at -3.04. Equity return is now at value -474.63, with -170.31 for asset returns.
Currently, EBITDA for the company is -38.77 million with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of -65.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In conclusion, Cellectar Biosciences Inc (CLRB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
